Clinical and Translational Radiation Oncology最新文献

{"title":"Application of a preclinical 18-gene classifier to patients with locally advanced HNSCC","authors":"Steffen Löck ,&nbsp;Lydia Koi ,&nbsp;Kristin Gurtner ,&nbsp;Fabian Lohaus ,&nbsp;Max Kemper ,&nbsp;Dominik Haim ,&nbsp;Inge Tinhofer ,&nbsp;Goda Kalinauskaite ,&nbsp;Martin Stuschke ,&nbsp;Maximilian Fleischmann ,&nbsp;Claus Rödel ,&nbsp;Anca-Ligia Grosu ,&nbsp;Jürgen Debus ,&nbsp;Claus Belka ,&nbsp;Stephanie Combs ,&nbsp;Simon Boeke ,&nbsp;Gustavo Baretton ,&nbsp;Michael Baumann ,&nbsp;Mechthild Krause ,&nbsp;Annett Linge","doi":"10.1016/j.ctro.2025.101067","DOIUrl":"10.1016/j.ctro.2025.101067","url":null,"abstract":"<div><div>In a previous preclinical trial on human HNSCC xenografts, 18 genes were predictive for adding cetuximab to fractionated radiotherapy. Here, we apply the corresponding 18-gene classifier to two HNSCC patient cohorts treated with combined radiochemotherapy (without cetuximab). We show that the classifier is related to EGFR expression and stratifies patients for loco-regional control (LRC) in both cohorts.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"56 ","pages":"Article 101067"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re-irradiation for recurrent esophageal cancer: clinical benefit, survival outcomes, and toxicity profile","authors":"Chiara Mattioli ,&nbsp;Lucy A. van Werkhoven ,&nbsp;M. Loi ,&nbsp;Joost J. Nuyttens","doi":"10.1016/j.ctro.2025.101068","DOIUrl":"10.1016/j.ctro.2025.101068","url":null,"abstract":"<div><h3>Background and purpose</h3><div>To evaluate survival and toxicity in patients with recurrent esophageal cancer treated with curative (cRT) and palliative (pRT) reirradiation.</div></div><div><h3>Materials and methods</h3><div>From May 2015 to August 2024, 41 patients with locally recurrent esophageal cancer received cRT or pRT. Toxicity was assessed using CTCAE v5.0. Overall survival (OS) was analyzed using the Kaplan-Meier method. Clinical benefit of pRT (reduction in dysphagia, pain or bleeding) was assessed 4 weeks after reRT.</div></div><div><h3>Results</h3><div>The cohort consisted of 41 patients (median age 73 years). At reirradiation, 36 patients received pRT (20 Gy/5fx or 30 Gy/10fx), and 5 received cRT (50.4 Gy/28fx with chemotherapy). Sixteen patients (39%) had metastatic disease (M1). Median OS was 11.9 months for M0 cRT, 9.8 months for M0 pRT, and 2.8 months for M1 pRT (p = 0.003). The pRT provided clinical benefit in 72% of patients: the median OS for M0 patients who did and did not experience symptoms improvement from reirradiation was 9.8 and 5 months, respectively; M1 patients with and without therapeutic effect had a median OS of 4.5 and 2.2 months, respectively (p &lt; 0.001). Acute toxicity was low, with 5 pRT patients requiring a nasogastric tube and 1 patient developing grade 3 skin toxicity. No grade ≥ 4 toxicities were reported.</div></div><div><h3>Conclusion</h3><div>Palliative reirradiation in patients with recurrent esophageal cancer showed clinical benefit in 72% of the patients, with impact on OS both in M0 and M1 patients and low rate of acute toxicity. These findings support the use of reirradiation as a feasible and effective strategy in selected patients with recurrent esophageal cancer.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"56 ","pages":"Article 101068"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Deep learning in CT-based organ-at-risk delineation for pediatric flank irradiation”: Methodological and clinical considerations","authors":"Abdullah Saad,&nbsp;Rutaba Darooj,&nbsp;Ayesha Ismail","doi":"10.1016/j.ctro.2025.101065","DOIUrl":"10.1016/j.ctro.2025.101065","url":null,"abstract":"<div><div>The study by Ding et al. on deep-learning-assisted organ-at-risk delineation for pediatric flank irradiation offers a valuable advancement toward automation in radiotherapy planning. However, several methodological and analytical gaps limit the confidence with which these findings can be generalized. Key issues include insufficient transparency of the manual annotation protocol and absence of baseline inter-observer variability metrics; possible circularity from using STAPLE consensus incorporating deep-learning contours; reliance solely on geometric similarity indices (Dice, HD95) without accompanying dosimetric validation; lack of uncertainty quantification or failure-mode analysis; and omission of workflow assessments beyond controlled settings. Together, these constraints obscure the true clinical impact of deep learning in radiotherapy contouring. Future investigations should prioritize transparent multicenter annotation standards, integrate probabilistic or uncertainty-aware models, include dosimetric endpoints, and evaluate performance within real-world clinical environments. Such measures will ensure that the promise of AI-assisted contouring translates into reproducible, safe, and clinically meaningful improvements in pediatric radiotherapy.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"56 ","pages":"Article 101065"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of excluding internal mammary node coverage on musculoskeletal dosimetry in breast radiotherapy","authors":"Stephen Lowell Ciocon ,&nbsp;Antonio de la Pena Villarreal ,&nbsp;Grace Lee ,&nbsp;Randa Kamel ,&nbsp;Mohammad Rahman ,&nbsp;Leigh Conroy ,&nbsp;Robert Bleakney ,&nbsp;Jennifer Croke ,&nbsp;Anne Koch ,&nbsp;Emma Mauti ,&nbsp;Jennifer Jones ,&nbsp;Eugene Chang ,&nbsp;Melissa Weidman ,&nbsp;Wey Leong ,&nbsp;Zhihui Amy Liu ,&nbsp;Xiang Y. Ye ,&nbsp;Jennifer Yin Yee Kwan ,&nbsp;Fei-Fei Liu","doi":"10.1016/j.ctro.2025.101077","DOIUrl":"10.1016/j.ctro.2025.101077","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;Breast cancer radiotherapy (RT) can lead to shoulder complications including weakness, restricted motion, and discomfort, affecting up to 40% of patients. The necessity to include the internal mammary nodes (IMNs) during breast and nodal irradiation for every patient remains under discussion, particularly for early-stage breast cancers. The dosimetric effect on nearby musculoskeletal (MSK) structures when targeting the IMNs remains to be completely understood; hence the focus of this current study.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This retrospective study included breast cancer patients who underwent lumpectomy and nodal sampling followed by adjuvant hypofractionated whole breast and regional nodal RT (4005 cGy in 15 fractions) who were treated between January 1, 2022, and November 30, 2023 at a single institution. MSK structures such as the bones (ribs, scapula), muscles (pectoralis, rhomboids), and joints (glenohumeral, acromioclavicular) were retrospectively contoured on the CT simulation images. Two RT plans (one with and one without IMN coverage) were created, and dosimetric parameters including mean (Dmean), near maximum (D2), near minimum (D98) and volumes received 15, 20 and 40 Gy (V15, V20, V40) were compared. Standardized mean difference between the plans was calculated for each dosimetric parameter, and Wilxocon’s signed-rank test was used for comparison. Univariable linear regression analysis was used to identify patient and tumor factors that were associated with more significant dosimetric differences.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A total of 30 breast cancer patients with a median age of 63 (range 30–82 years) were selected for analysis. The location of tumours included 15 (50 %) in the right breast, and 15 (50 %) in the left breast; with 10 (33 %) centrally, 10 (33 %) medially, and 10 (33 %) were laterally-located within the breast. The pathologic T stage included 6 (20 %) T0/Tis, 11 (37 %) T1, and 13 (43 %) T2. Seven patients (23 %) were N0, 19 (63 %) were N1, and 4 (13 %) were N2a. Nine patients received adjuvant chemotherapy, 11 neoadjuvant chemotherapy, and 10 patients received no chemotherapy.&lt;/div&gt;&lt;div&gt;The exclusion of IMN coverage led to significantly decreased Dmean for muscle groups in the posterior, posterolateral, lateral, anterior and antero-lateral-posterior regions. Specifically, the largest absolute reductions included teres major (Dmean 340 cGy), subscapularis (320 cGy), serratus anterior (241 cGy), latissimus dorsi (232 cGy), chestwall (209 cGy), and the pectoralis minor (37 cGy) muscles. Significant differences were also observed for V40 and V15 of pectoralis minor (V40 of 12 %), pectoralis major (V40 of 10 %), and for both subscapularis and teres major (V15 of 8 %) muscles.&lt;/div&gt;&lt;div&gt;Patient factors that were associated with greater dosimetric differences included younger age, larger breast size, larger tumor cavity, and non-central tumor locations.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclu","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"56 ","pages":"Article 101077"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145614552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vascular calcifications in early-breast radiotherapy planning-CT: Opportunistic detection and cardiovascular risk assessment","authors":"Ana Aurora Diaz-Gavela ,&nbsp;Julio Fernández-Mata ,&nbsp;Elia del Cerro-Peñalver ,&nbsp;Sofía Sanchez-Garcia ,&nbsp;Cristina Andreu-Vazquez ,&nbsp;Israel John Thuissard-Vasallo ,&nbsp;David Sanz-Rosa ,&nbsp;Lucía González-Cortijo ,&nbsp;Marina Peña-Huertas ,&nbsp;Victor Duque-Santana ,&nbsp;Luis Leonardo Guerrero ,&nbsp;Yolanda Molina Lopez ,&nbsp;Felipe Couñago","doi":"10.1016/j.ctro.2025.101076","DOIUrl":"10.1016/j.ctro.2025.101076","url":null,"abstract":"<div><h3>Objective</h3><div>To determine the prevalence of vascular calcifications on radiotherapy-planning CTs in women with early breast cancer (BC) and their association with subsequent cardiovascular (CV) events.</div></div><div><h3>Material and methods</h3><div>Single-center retrospective study of patients who received adjuvant radiotherapy for early BC after breast conserving surgery (2009–2019). Planning CTs were visually assessed for vascular calcifications and the incidence of CV events during follow-up was determined. Comparative analyses of clinical characteristics were conducted across groups stratified by calcification status. Multivariate logistic regression served to evaluate CV event risk, with adjustment for conventional cardiovascular risk factors (CVRF).</div></div><div><h3>Results</h3><div>The study included 882 patients. The median (IQR) age was 52 (46–62) years. Calcifications were found in 340 patients (38.5 %), 154 (17.5 %) in coronary arteries. Patients with calcifications were significantly older (62 vs. 48 years) and more likely to present CVRF, including hypertension (32.6 % vs. 10.0 %), dyslipidemia (34.7 % vs. 15.3 %), and diabetes (11.5 % vs. 3.1 %). Median follow-up was 8 years (6–10), with 35 patients (4.0 %) experiencing a CV event. Vascular calcification was associated with a significantly higher incidence of CV events (7.1 % vs. 2.0 %; OR = 3.7; 95 % CI: 1.8–7.6). The presence of coronary calcifications, adjusted for age and conventional CVRF, was associated with a 2.86-fold (95 % CI: 1.05–7.78) higher risk of a CV event.</div></div><div><h3>Conclusion</h3><div>This study shows that vascular calcifications detected incidentally on radiotherapy planning CTs for early BC are common and associated with an increased risk of CV events that is independent of conventional CVRF. These findings suggest that planning CTs in these patients should be routinely reviewed to check for vascular calcifications.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"56 ","pages":"Article 101076"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of loco-regional recurrences using deformable image registration after isotoxic high dose stereotactic body radiotherapy in localised pancreatic cancer","authors":"Martin Manderlier ,&nbsp;Sara Poeta ,&nbsp;Jean-Luc Engelholm ,&nbsp;Akos Gulyban ,&nbsp;Jean-Luc Van Laethem ,&nbsp;Christelle Bouchart","doi":"10.1016/j.ctro.2025.101081","DOIUrl":"10.1016/j.ctro.2025.101081","url":null,"abstract":"<div><h3>Background and Purpose</h3><div>Pancreatic ductal adenocarcinoma is a highly aggressive malignancy with poor survival outcomes. Neoadjuvant treatments, including radiotherapy, have been developed to improve resectability and survival rates. This study evaluates loco-regional recurrence (LRR) patterns after isotoxic high-dose stereotactic body radiotherapy (iHD-SBRT) for localized pancreatic cancer using deformable image registration (DIR).</div></div><div><h3>Materials and Methods</h3><div>Patients with borderline/locally advanced pancreatic adenocarcinoma treated between January 2018 and January 2021 were included. Treatment involved modified FOLFIRINOX chemotherapy, iHD-SBRT, and surgery, if feasible. LRRs identified via CT/MRI during follow-up were mapped back onto initial radiotherapy planning using validated DIR workflows. Recurrences were classified as in-field (IF), marginal (M), or out-of-field (OF).</div></div><div><h3>Results</h3><div>Among 41 patients, LRRs were identified in 17 (10 via CT, 7 via MRI). The majority of LRRs were classified as OF (53 %, n = 9), with 23.5 % (n = 4) each in IF and M categories. Marginal recurrences were located near major abdominal vessels, such as the superior mesenteric artery and coeliac artery. DIR quality metrics, including DICE and MDA, validated the accuracy of the mapping process.</div></div><div><h3>Conclusion</h3><div>Image based evaluation of loco-regional recurrence is an important part of the assessment of patients treated with iHD-SBRT for localised pancreatic cancer. DIR-based analysis emphasized the importance of expanding the tumor-vessel interface (TVI) structure in radiotherapy planning to include the full circumference of adjacent vessels with a 5 mm margin. DIR-based analysis highlighted that several marginal recurrences occurred in proximity to perivascular regions, suggesting a potential benefit of expanding perivascular target coverage in future treatment planning.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"56 ","pages":"Article 101081"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of prostate recurrence after focal salvage prostate brachytherapy for radiorecurrent prostate cancer","authors":"Alba Domínguez Domínguez ,&nbsp;Niels den Haan ,&nbsp;Jan Wiersma ,&nbsp;Josephina C.C. Koppes ,&nbsp;Karel A. Hinnen ,&nbsp;Bradley R. Pieters","doi":"10.1016/j.ctro.2025.101043","DOIUrl":"10.1016/j.ctro.2025.101043","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Focal high-dose-rate (HDR) salvage brachytherapy has emerged as a treatment for radiorecurrent prostate cancer. This study aims to evaluate patterns of recurrence after focal salvage brachytherapy and to assess the adequacy of current treatment margins.</div></div><div><h3>Materials and methods</h3><div>Between March 2015 and December 2021, 39 patients with radiorecurrent prostate cancer underwent focal HDR brachytherapy. All patients had biopsy-confirmed local recurrence and were staged using Choline- or PSMA-PET/CT and multiparametric MRI. A 5 mm margin around the GTV was applied to define the CTV. Post-treatment recurrences were analyzed using rigid image registration of PET/CT and MRI to assess spatial relationships among the initial recurrence (Rec1), the recurrence following salvage brachytherapy (Rec2), and the brachytherapy dose distribution. The recurrences were categorized into infield, marginal, and outfield based on overlap of relapse with the treated CTV and based on dose received on the site of the relapse. Additionally, spatial analysis measured minimal distances between Rec1 and Rec2.</div></div><div><h3>Results</h3><div>Nineteen of 39 patients experienced clinical recurrence, with 12 exhibiting 25 local lesions. Based on spatial overlap, 20 % of Rec2 lesions were infield, 28 % marginal, and 52 % outfield. Dose-based classification indicated 52 % infield, 8 % marginal, and 40 % outfield recurrence. The median distance between Rec1 and Rec2 in outfield cases was 11.9–13.4 mm.</div></div><div><h3>Conclusion</h3><div>A substantial proportion of local recurrences after focal salvage brachytherapy occur outside the treated volume. Current 5 mm margins may be insufficient.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"56 ","pages":"Article 101043"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145047411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of target volume coverage and liver exposure in high-dose-rate interstitial brachytherapy and in silico MR LINAC-based stereotactic body radiotherapy plans for colorectal liver metastases","authors":"Sina Mansoorian ,&nbsp;Svenja Hering ,&nbsp;Jan Hofmaier ,&nbsp;Yuqing Xiong ,&nbsp;Helmut Weingandt ,&nbsp;Maya Rottler ,&nbsp;Franziska Walter ,&nbsp;Paul Rogowski ,&nbsp;Max Seidensticker ,&nbsp;Jens Ricke ,&nbsp;Claus Belka ,&nbsp;Stefanie Corradini ,&nbsp;Chukwuka Eze","doi":"10.1016/j.ctro.2025.101030","DOIUrl":"10.1016/j.ctro.2025.101030","url":null,"abstract":"<div><h3>Background</h3><div>This study compared the plan quality and dosimetric parameters of single-fraction (SF) MR-LINAC (MRL)-based stereotactic body radiotherapy (SBRT) with delivered high-dose-rate interstitial brachytherapy (HDR-iBT) for colorectal liver metastases (CRLM).</div></div><div><h3>Methods</h3><div>Between August 2017 and March 2019, 26 patients with a total of 45 CRLM were treated in 28 sessions using HDR-iBT with 1 × 25 Gy and were retrospectively included in this study. For each patient, an <em>in silico</em> MRL-based SBRT plan was generated using the corresponding iBT CT dataset. In the iBT plans, a single fraction of 25 Gy was prescribed to the periphery of the gross tumor volumes (GTVs), while in the SBRT plans, the same dose was prescribed to the 80% isodose line covering the planning target volumes (PTVs). We compared the dosimetric properties of the delivered HDR-iBT and MRL-based SBRT plans.</div></div><div><h3>Results</h3><div>Median GTV was 3.83 cc (range: 0.13–92.58 cc) and median PTV_SBRT was 15.47 cc (range: 2.68–164.17 cc). Both HDR-iBT and SBRT demonstrated excellent GTV coverage, with no statistically significant differences in GTV D_98% (28.82 ± 2.57 Gy vs. 28.92 ± 0.88 Gy, p = 0.9). HDR-iBT achieved superior GTV D_95% (31.62 ± 3.20 Gy vs. 29.22 ± 0.74 Gy, p &lt; 0.01) and GTV D_50% (64.71 ± 12.78 Gy vs. 30.22 ± 0.52 Gy, p &lt; 0.01). Uninvolved liver dose metrics were higher in the SBRT plans compared to iBT, with a median relative difference in V_5Gy of 5.29% (range: −13.69% to + 17.89%, p &lt; 0.01) and a smaller relative difference in V_10Gy of 1.5% (range: −7.74% to + 11.26%, p &lt; 0.01).</div></div><div><h3>Conclusion</h3><div>Our comparison indicates MRL-based SBRT to liver lesions is feasible, achieving adequate target volume coverage without clinically relevant violations of organ-at-risk (OAR) constraints.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"56 ","pages":"Article 101030"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145010898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Clinical outcomes of pelvic bone marrow sparing radiotherapy for cervical cancer: A systematic review and meta-analysis of randomised controlled trials”. [Clin. Translat. Radiat. Oncol. 47 (2024) 100801]","authors":"Marcin Miszczyk ,&nbsp;Tao Wu ,&nbsp;Kasper Kuna ,&nbsp;Magdalena Stankiewicz ,&nbsp;Emilia Staniewska ,&nbsp;Zuzanna Nowicka ,&nbsp;Ziqin Chen ,&nbsp;Loren K. Mell ,&nbsp;Joachim Widder ,&nbsp;Maximilian Schmidt ,&nbsp;Rafał Tarnawski ,&nbsp;Paweł Rajwa ,&nbsp;Shahrokh F. Shariat ,&nbsp;Pixiao Zhou","doi":"10.1016/j.ctro.2025.101057","DOIUrl":"10.1016/j.ctro.2025.101057","url":null,"abstract":"","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"56 ","pages":"Article 101057"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145732967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro determination of patient-specific variation challenges the universal RBE gold standard for proton radiation therapy","authors":"Anna Kirstein ,&nbsp;Dan Ionascu ,&nbsp;Michael A.S. Lamba ,&nbsp;Bianca M. Ruffolo ,&nbsp;Katherine J. Crail ,&nbsp;Anthony E. Mascia ,&nbsp;Mathieu G. Sertorio ,&nbsp;Benjamin H. Hinrichs ,&nbsp;Chad Zender ,&nbsp;Maria A. Lehn ,&nbsp;Trisha M. Wise-Draper ,&nbsp;John P. Perentesis ,&nbsp;Yi Zheng ,&nbsp;Susanne I. Wells","doi":"10.1016/j.ctro.2025.101046","DOIUrl":"10.1016/j.ctro.2025.101046","url":null,"abstract":"","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"56 ","pages":"Article 101046"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145109636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}